A practical reference on triple agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
=== Available forms === Nalbuphine is available in two concentrations, 10 mg and 20 mg of nalbuphine hydrochloride per mL. Both strengths contain 0.94% sodium citrate hydrous, 1.26% citric acid anhydrous, 0.1% sodium metabisulfite, and 0.2% of a 9:1 mixture of methylparaben and propylparaben as preservatives; pH is adjusted, if necessary, with hydrochloric acid. The 10 mg/mL strength contains 0.1% sodium chloride. The drug is also available in a sulfite and paraben-free formulation in two concentrations, 10 mg and 20 mg of nalbuphine hydrochloride per mL. One mL of each strength contains 0.94% sodium citrate hydrous, 1.26% citric acid anhydrous; pH is adjusted, if necessary, with hydrochloric acid. The 10 mg/mL strength contains 0.2% sodium chloride. An investigational extended-release oral formulation is under development by Trevi Therapeutics.
=== Neoantigens === Many tumors express mutations. These mutations potentially create new targetable antigens (neoantigens) for use in T-cell immunotherapy. The presence of CD8+ T cells in cancer lesions, as identified using RNA sequencing data, is higher in tumors with a high mutational burden. The level of transcripts associated with the cytolytic activity of natural killer cells and T cells positively correlates with mutational load in many human tumors. In non–small cell lung cancer patients treated with lambrolizumab, mutational load shows a strong correlation with clinical response. In melanoma patients treated with ipilimumab, the long-term benefit is also associated with a higher mutational load, although less significantly. The predicted MHC binding neoantigens in patients with a long-term clinical benefit were enriched for a series of tetrapeptide motifs that were not found in tumors of patients with no or minimal clinical benefit. However, human neoantigens identified in other studies do not show the bias toward tetrapeptide signatures. Finally, effectiveness of neoantigens may also be regulated by the specific HLA repertoire possessed by specific patient sub-groups.
Rogue taxidermy (sometimes referred to as "taxidermy art" or "botched taxidermy") is a form of mixed media sculpture. Rogue taxidermy art references traditional trophy or natural history museum taxidermy, but is not always constructed out of taxidermied animals; it can be constructed entirely from synthetic materials. Additionally, rogue taxidermy is not necessarily figurative, as it can be abstract and does not need to resemble an animal. It can be a small decorative object or a large-scale room-sized installation. There is a very broad spectrum of styles within the genre, some of which falls into the category of mainstream art. "Rogue taxidermy" describes a wide variety of work, including work that is classified and exhibited as fine art. Neither the term, nor the genre, emerged from the world of traditional taxidermy. The genre was born from forms of fine art that utilize some of the components found in the construction of a traditional taxidermy mount. The term "rogue taxidermy" was coined in 2004 by an artist collective called The Minnesota Association of Rogue Taxidermists. The Minneapolis-based group was founded by artists Sarina Brewer, Scott Bibus, and Robert Marbury as a means to unite their respective mediums and differing styles of sculpture. The definition of rogue taxidermy set forth by the individuals who formed the genre (Brewer, Bibus, and Marbury) is: "A genre of pop-surrealist art characterized by mixed media sculptures containing conventional taxidermy-related materials that are used in an unconventional manner".
Sources: en.wikipedia.org
=== Aspirational use as green chemicals === Natural polyphenols have long been proposed as renewable precursors to produce plastics or resins by polymerization with formaldehyde, as well as adhesives for particleboards. The aims are generally to make use of plant residues from grape, olive (called pomaces), or pecan shells left after processing.
=== 19 May === Five people were killed in a double-tap airstrike, a common Russian tactic believed to deliberately target first responders, in the Mala Danylivka suburb of Kharkiv. Five others were killed in airstrikes in Kupiansk Raion, while one person was killed by shelling in Vovchansk. Russian-installed officials in Kherson Oblast claimed that one person was killed in a Ukrainian drone strike on a minibus in Radensk, while one person was injured in a separate attack in Donetsk. Ukrainian forces claimed to have sunk the Russian minesweeper Kovrovets and the missile ship Tsiklon, while Russian forces claimed to have shot down nine ATACMS and a drone over Crimea. The SBU claimed that drones struck the Slavyansk oil refinery and the Kushchyovskaya airbase in Russia's Krasnodar Krai. Explosions occurred at both sites, with Ukraine claiming that aircraft were hit at the airbase. The refinery was temporarily closed to assess the damage.
== Specialty areas == Many medical laboratory scientists are generalists, skilled in most areas of the clinical laboratory. However, some are specialists, qualified by unique undergraduate education or additional training to perform more complex analyses than usual within a specific field. Specialties include clinical biochemistry, hematology, coagulation, microbiology, bacteriology, toxicology, virology, parasitology, mycology, immunology, immunohematology (blood bank), histopathology, histocompatibility, cytopathology, genetics, cytogenetics, electron microscopy, and IVF labs. Medical technologists specialty may use additional credentials, such as "SBB" (specialist in blood banking), "SM" (specialist in microbiology), "SC" (specialist in chemistry), or "SH" (specialist in hematology) from the American Society for Clinical Pathology (ASCP). These additional notations may be appended to the base credential, for example, "MLS (ASCP), SBB (ASCP)". Additional information can be found in the ASCP Procedures for Examination & Certification. Andrology laboratory scientist (such as those working for a sperm bank), embryology laboratory scientist, and molecular diagnostics technologist certifications are provided by the American Association of Bioanalysts; those with the certifications are classified as ALS (AAB), ELS (AAB), and MDxT (AAB), respectively.
Sources: en.wikipedia.org
Fascinated by the theories of Max Weber, Peukert began his last book with a quote from Weber who warned that the modern age would bring about "experts without spirit" and the "hedonist without a heart". Peukert went on to write about this modern age: "At its beginning there is immense loneliness and religious distress, which however help to bring about an unsuspected enhancement of the individual's attachment to this life, his rational control of the world and intellectual autonomy; at its end we may find routine "enslavement to the future", emptied of all meaning and causing the dynamic, expansive force of rationalization to ossify. In both cases, however, the growing pressure of suffering is the price paid for the gain in rationality". For Peukert, inspired by the theories of Weber, saw the purpose of his work to help foster experts who have spirit and hedonists with a heart.Though Peukert worked primarily as a historian (an occupation that has far greater prestige in Germany than it does in the English-speaking world), he also wrote about at times about literacy theory, philosophy, and anthropology. Peukert was also politically engaged, and his last essay written shortly before his death, Rechtsradikalismus in historischer Perspektive (Right-wing Radicalism in the Historical Perspective) warned against the rise of the party The Republicans led by the former SS-Unterscharführer Franz Schönhuber, which had some popular support in Germany with its call for a ban on Turkish "guest workers".
== Astronomy and spaceflight == There is no scientific evidence that the motion of stars, planets, and other celestial bodies influences the fates of humans, and astrology has repeatedly been shown to have no explanatory power in predicting future events. Astronauts in orbit have the sensation of being weightless because they are in free fall around the Earth, not because they are so far away from the Earth that its gravitational pull is negligible. For example, on the International Space Station the Earth's gravity is nearly 90% as strong as at the surface. Objects orbiting in space would not remain in orbit if not for the gravitational force, and gravitational fields extend infinitely, though the strength of the gravitational force is attenuated with distance. There is no limit to the distance across which two objects exert gravitational forces upon one another. The dark side of the Moon receives about the same amount of light from the Sun as the near side. Since the same side of the Moon always faces the Earth due to tidal locking, the far side had not been seen until Luna 3 photographed it in 1959. Hence, "dark" refers to the far side being unseen from Earth, not to any lack of illumination by the Sun. Black holes have the same gravitational effects as any other equal mass in their place. They will draw objects towards them according to distance and mass, just as any other celestial body does, except at very close distances to the black hole, comparable to its Schwarzschild radius.
=== Key-wind, key-set movements === The first pocket watches, since their creation in the 16th century, up until the third quarter of the 19th century, had key-wind and key-set movements. A watch key was necessary to wind the watch and to set the time. This was usually done by opening the caseback and putting the key over the winding-arbor (which was set over the watch's winding-wheel, to wind the mainspring) or by putting the key onto the setting-arbor, which was connected with the minute-wheel and turned the hands. Some watches of this period had the setting-arbor at the front of the watch, so that removing the crystal and bezel was necessary to set the time. Watch keys are the origin of the class key, common paraphernalia for American high-school and university graduation. Many keywind watch movements make use of a fusee, to improve isochronism. The fusee is a specially cut conical pulley attached by a fine chain to the mainspring barrel. When the spring is fully wound (and its torque the highest), the full length of the chain is wrapped around the fusee and the force of the mainspring is exerted on the smallest diameter portion of the fusee cone. As the spring unwinds and its torque decreases, the chain winds back onto the mainspring barrel and pulls on an increasingly larger diameter portion of the fusee. This provides a more uniform amount of torque on the watch train, and thus results in more consistent balance amplitude and better isochronism.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.